



## **Osivax appoints Dr. Delphine Guyon-Gellin as Chief Business Development Officer**

**This recruitment brings strategic capabilities to drive the development of Osivax's lead candidate, a breakthrough influenza vaccine**

**Lyon, France – January 24th, 2018** – Osivax, a biopharmaceutical company currently focused on the development of a breakthrough influenza vaccine, announced today that the Company is strengthening its management team with the appointment of Dr. Delphine Guyon-Gellin as Chief Business Development Officer.

"We are delighted to welcome Delphine Guyon-Gellin in our leadership team. Delphine's extensive experience working with leading pharmaceutical companies, along with her in-depth expertise on strategy in vaccines, will be pivotal for Osivax as we enter the clinical phase for our lead influenza vaccine candidate", said Alexandre Le Vert, CEO and cofounder of Osivax. "Her arrival will strengthen our capacities to better interact and build partnerships with the influenza community at large".

Delphine Guyon-Gellin will be responsible for Corporate Development and Strategy at Osivax. As a Doctor of Veterinary Medicine with a strong experience in strategic consulting, she brings to Osivax her valuable global experience in solving strategic questions in Healthcare. Before joining Osivax, she worked for seven years at the Boston Consulting Group in Paris and then London and was involved in various strategic assignments in Healthcare, including many projects in Vaccines. Prior to this she worked for AEC Partners a strategic consulting firm specialised in Healthcare. Delphine graduated from National Veterinary School of Maisons-Alfort and holds a Master degree from HEC.

"As the holy grail in influenza prevention is to develop a universal flu vaccine, Osivax has a disruptive technology platform to induce powerful immune response against highly conserved influenza antigens" added Delphine Guyon-Gellin "As such, Osivax is well-positioned to make its mark and develop the next generation of influenza vaccines, and I look forward to joining the team at this pivotal time. Beyond influenza, Osivax' technology platform is highly promising to address other severe unmet needs in oncology and infectious diseases."

### **About Influenza**

With 250,000 to 500,000 deaths annually globally, including tens of thousands in the US and Europe (56,000 deaths in the US alone in 2012), Influenza remains a devastating disease.



Current seasonal vaccines are only partially effective, especially for patients over 65 years old (25% effectiveness in the 2016-17 season in the US, according to the CDC, the Atlanta, GA based Center for Disease Controls and Prevention).

**About OVX836**

OVX836 is a breakthrough, wide-spectrum influenza vaccine that is in late-stage preclinical development, with a phase I clinical trial planned to start in 2018.

OVX836 activates a CD8 T-cell immune response against the influenza nucleoprotein (NP), a well-conserved internal protein essential to the replication of the virus. Vaccines triggering such immune response (CD8 T-cell responses against NP) represent a disruptive and promising path to a breakthrough improvement of current flu vaccines.

OVX836 will be used in combination with seasonal influenza vaccines.

**About Osivax**

Osivax is a biopharmaceutical company focused on vaccines and leveraging on oligoDOM®, a patented technology platform spun-off from Imaxio SA. Osivax focuses on its flagship project: OVX836, a breakthrough influenza vaccine candidate, with the goal to rapidly start a phase I clinical trial.

The company partners with international renown academic structures, including the Jenner Institute at Oxford University (UK), the German Cancer Research Center (DKFZ), Inserm, CNRS and the Léon Bérard Cancer Center (France).

Osivax was founded in 2017 as a spin-off of Imaxio SA.

For further information: [www.osivax.com](http://www.osivax.com)

Contact

Alexandre LE VERT

[contact@osivax.com](mailto:contact@osivax.com)

+33 (0)4 37 65 55 03